The ideal treatment regimen should cause good symptom control through maximum tumour regression with a prolonged progression-free interval and minimal toxicity.
In this study, we administered GM-CSF s.c. after peroral treatment with etoposide to overcome the dose-limiting myelotoxicity of etoposide and to increase the dose intensity per treatment cycle, thereby increasing the response rate, which ultimately would lead to a prolonged progression-free interval and a shorter time to response.
On the other hand, neurodegenerative conditions like MS and ALS owe their prolonged progression to a slow and persistent increase in proinflammatory cytokines.
Clinical studies have shown that a low dose of decitabine can alter the DNA methylation of genes and cancer pathways, thereby restoring sensitivity to carboplatin in heavily pretreated ovarian cancer patients who progressed or recurred within 6 months after platinum-based chemotherapy, resulting in a high response rate and prolonged progression free survival [ 12].
A functional initiation complex can only be reassembled after prolonged progression of post-termination ribosomes, allowing the initiation at the MCS start codon and the induction of GCN4 under stress conditions.
Prolonged progression may be anticipated in disciplines which further rely on technology such as sailing and cycling.
Moreover, PPG-treated cells exhibited prolonged progression of mitosis and delay its onset.
They concluded that a higher composite pathological tumour response score was significantly correlated with a prolonged progression-free survival (P=0.0016) and OS (P=0.017).
Sunitinib is approved as first-line treatment for renal cell carcinoma, with a 31% response rate and a prolonged progression-free survival (PFS) of 11 months [ 14].
In patients with locally advanced or metastatic breast cancer, treatment efficacy is evaluated by tumour shrinkage that seems to be associated with a prolonged progression-free survival and OS (Bruzzi et al, 2005).
Patients with a high relative decrease in the plasma levels of total antioxidant biomarker FRAP during radiotherapy have a prolonged progression-free survival as shown in figure 1B, that remained significant after adjusting for confounding factors (p = 0.05) (Table 6).
